Emergency Medicine

HIV / AIDS

Medical News

Primary Care

Surgery

Home » Primary Care, diabetes

Glaxo Calls Congressional Report Incomplete

Submitted by MedicalReplies on Thursday, 25 February 2010No Comment

GlaxoSmithKline disputes a congressional report suggesting rosiglitazone (Avandia) be pulled from the market, charging that the assessment “fails to present an accurate, balanced, or complete view” of data on the diabetes drug.

Here is the original:
Glaxo Calls Congressional Report Incomplete

You may also like:

Leave your response!

Add your comment below, or trackback from your own site. You can also subscribe to these comments via RSS.

Be nice. Keep it clean. Stay on topic. No spam.

You can use these tags:
<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

This is a Gravatar-enabled weblog. To get your own globally-recognized-avatar, please register at Gravatar.

*
To prove you're a person (not a spam script), type the security word shown in the picture.
Anti-spam image